Global X Genomics & Biotechnology ETFGNOM
GNOM
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
87% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 15
8.47% less ownership
Funds ownership: 44.33% [Q4 2024] → 35.86% (-8.47%) [Q1 2025]
16% less funds holding
Funds holding: 67 [Q4 2024] → 56 (-11) [Q1 2025]
38% less capital invested
Capital invested by funds: $30M [Q4 2024] → $18.5M (-$11.5M) [Q1 2025]
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $37K
Research analyst outlook
We haven’t received any recent analyst ratings for GNOM.
Financial journalist opinion
Neutral
Seeking Alpha
2 weeks ago
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.
Neutral
Seeking Alpha
3 months ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Positive
Zacks Investment Research
6 months ago
Best-Performing ETF Areas of Last Week
Wall Street was upbeat last week with the Dow Jones and the S&P 500 hitting all-time highs last week.
Positive
InvestorPlace
11 months ago
The 3 Best Gene Editing Stocks to Buy in July 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. With the technology, we can fix faulty genes, or replace them with healthier genes in an attempt to cure diseases or help the body fight disease.
Positive
InvestorPlace
1 year ago
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
Genomics is the future of medicine. With it, companies are racing to shed light on human health and disease.
Positive
InvestorPlace
1 year ago
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023.
Negative
Seeking Alpha
1 year ago
GNOM: Genomics Still Waiting For Its 'ChatGPT' Moment
GNMO invests across companies benefiting from advancements in the field of genomics within biotechnology. The fund's historical performance has been poor amid volatile stock prices for underlying holdings. Genomics may be the future, but still missing a blockbuster application to drive a wave of bullish momentum into the segment.
Positive
InvestorPlace
1 year ago
3 Stocks That Could Be the Next Big Thing in Gene Editing
Gene editing could revolutionize how millions of patients are treated all over the world. That could create big opportunities for some of the most exciting gene-editing stocks.
Positive
InvestorPlace
1 year ago
3 Gene Editing Stocks With Unprecedented Surge Potential
Gene editing is revolutionizing medicine. For example, just weeks ago, the U.S. Federal Drug Administration approved a new gene-editing treatment for sickle cell disease and transfusion-dependent beta-thalassemia, a genetic disorder that prevents the production of hemoglobin in the blood and requires regular blood transfusions.
Positive
InvestorPlace
1 year ago
3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential
Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.
Charts implemented using Lightweight Charts™